Profile data is unavailable for this security.
About the company
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
- Revenue in USD (TTM)0.00
- Net income in USD-303.27m
- Incorporated2015
- Employees168.00
- LocationPraxis Precision Medicines Inc99 High Street, 30th FloorBOSTON 02110United StatesUSA
- Phone+1 (617) 300-8460
- Fax+1 (302) 655-5049
- Websitehttps://praxismedicines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belite Bio Inc (ADR) | 0.00 | -49.38m | 6.66bn | 25.00 | -- | -- | -- | -- | -1.55 | -1.55 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -36.85 | -- | -36.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| Arcellx Inc | 22.29m | -228.93m | 6.67bn | 209.00 | -- | 16.42 | -- | 299.27 | -4.06 | -4.06 | 0.3945 | 6.95 | 0.0339 | -- | 7.31 | 106,631.60 | -34.81 | -28.60 | -42.17 | -34.05 | -- | -- | -1,027.26 | -274.64 | -- | -- | 0.00 | -- | -79.35 | -- | -113.26 | -- | 21.25 | -- |
| Kymera Therapeutics Inc | 39.21m | -311.35m | 7.36bn | 238.00 | -- | 4.64 | -- | 187.60 | -3.68 | -3.68 | 0.4642 | 19.42 | 0.0288 | -- | -- | 164,747.90 | -22.89 | -24.17 | -24.23 | -27.06 | -- | -- | -794.06 | -329.38 | -- | -- | 0.0021 | -- | -16.70 | 2.87 | -39.08 | -- | -30.75 | -- |
| Cytokinetics, Inc. | 88.04m | -784.96m | 7.57bn | 673.00 | -- | -- | -- | 85.94 | -6.53 | -6.53 | 0.733 | -5.37 | 0.0623 | -- | 5.12 | 130,815.80 | -55.55 | -49.49 | -64.23 | -55.60 | -- | -- | -891.60 | -897.66 | -- | -11.95 | 2.33 | -- | 376.56 | 9.54 | -33.15 | -- | 17.55 | -- |
| Nuvalent Inc | 0.00 | -425.38m | 7.96bn | 228.00 | -- | 6.35 | -- | -- | -5.85 | -5.85 | 0.00 | 15.96 | 0.00 | -- | -- | 0.00 | -33.30 | -27.97 | -35.31 | -29.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.13 | -- | -- | -- |
| ICON PLC | 8.10bn | 599.48m | 8.27bn | 39.80k | 14.64 | 0.8857 | 8.37 | 1.02 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -144.34m | 8.79bn | 18.30k | -- | 2.78 | 33.67 | 2.19 | -2.96 | -2.96 | 80.79 | 64.30 | 0.5477 | 9.04 | 5.62 | 219,419.80 | -1.94 | 3.42 | -2.28 | 4.01 | 34.98 | 36.22 | -3.54 | 6.37 | 1.02 | 3.43 | 0.3999 | 0.00 | -0.8545 | 6.55 | -1,501.75 | -- | 5.64 | -- |
| Vaxcyte Inc | 0.00 | -766.63m | 8.92bn | 507.00 | -- | 3.02 | -- | -- | -5.63 | -5.63 | 0.00 | 20.49 | 0.00 | -- | -- | 0.00 | -23.54 | -24.62 | -24.86 | -26.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -65.25 | -- | 118.08 | -- |
| Arrowhead Pharmaceuticals Inc | 1.09bn | 202.27m | 9.01bn | 711.00 | 41.75 | 15.55 | 34.82 | 8.26 | 1.54 | 1.54 | 7.90 | 4.14 | 0.8335 | -- | 9.86 | 1,534,432.00 | 17.84 | -25.96 | 21.44 | -30.82 | -- | -- | 21.41 | -76.01 | -- | 5.91 | 0.5068 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 9.05bn | 3.10k | 113.92 | 4.48 | 49.24 | 7.44 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Praxis Precision Medicines Inc | 0.00 | -303.27m | 9.21bn | 168.00 | -- | 9.49 | -- | -- | -13.45 | -13.45 | 0.00 | 34.85 | 0.00 | -- | -- | 0.00 | -42.68 | -61.92 | -45.82 | -68.99 | -- | -- | -- | -9,004.13 | -- | -- | 0.00 | -- | -100.00 | -- | -65.88 | -- | -- | -- |
| Tempus AI Inc | 1.27bn | -245.03m | 9.53bn | 3.80k | -- | 19.34 | -- | 7.49 | -1.41 | -1.41 | 7.30 | 2.76 | 0.7946 | 10.52 | 5.46 | 334,681.30 | -15.31 | -41.14 | -19.31 | -55.06 | 62.74 | 54.59 | -19.27 | -55.73 | 3.00 | -3.90 | 0.7161 | -- | 83.41 | 46.57 | 67.17 | -- | 15.24 | -- |
| Madrigal Pharmaceuticals Inc | 958.40m | -288.28m | 9.99bn | 915.00 | -- | 16.51 | -- | 10.43 | -12.85 | -12.85 | 42.72 | 26.39 | 0.8327 | 1.03 | 10.18 | 1,047,435.00 | -25.05 | -53.85 | -31.64 | -68.43 | 94.14 | -- | -30.08 | -146.24 | 3.77 | -- | 0.3606 | -- | 432.05 | -- | 38.12 | -- | 59.68 | -- |
| Exelixis Inc | 2.32bn | 782.57m | 10.66bn | 1.08k | 14.74 | 4.98 | 13.13 | 4.59 | 2.78 | 2.78 | 8.23 | 8.23 | 0.8011 | 3.80 | 8.40 | 2,154,249.00 | 27.02 | 13.68 | 31.41 | 15.65 | 96.39 | 96.33 | 33.73 | 20.55 | 3.50 | -- | 0.00 | 0.00 | 6.98 | 18.63 | 50.13 | 47.58 | -22.60 | -- |
| Immunitybio Inc | 113.29m | -351.40m | 10.73bn | 691.00 | -- | -- | -- | 94.75 | -0.3898 | -0.3898 | 0.1232 | -0.4946 | 0.2561 | 0.164 | 5.04 | 163,947.90 | -79.44 | -101.72 | -91.74 | -204.78 | 99.34 | -- | -310.25 | -1,629.94 | 5.08 | -1.75 | 2.64 | -- | 668.31 | 184.76 | 15.03 | -- | 20.57 | -- |
Data as of Mar 03 2026. Currency figures normalised to Praxis Precision Medicines Inc's reporting currency: US Dollar USD
54.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 3.19m | 11.44% |
| Perceptive Advisors LLCas of 31 Dec 2025 | 2.00m | 7.17% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.75m | 6.30% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.28m | 4.60% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 1.27m | 4.58% |
| Orbis Investment Management Ltd.as of 31 Dec 2025 | 1.26m | 4.51% |
| Baker Bros. Advisors LPas of 31 Dec 2025 | 1.13m | 5.53% |
| Adage Capital Management LPas of 31 Dec 2025 | 965.31k | 3.47% |
| Cormorant Asset Management LPas of 31 Dec 2025 | 950.00k | 3.41% |
| Driehaus Capital Management LLCas of 31 Dec 2025 | 933.06k | 3.35% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
